<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614029</url>
  </required_header>
  <id_info>
    <org_study_id>ZX001-0601</org_study_id>
    <nct_id>NCT00614029</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose, Four-way Crossover Study to Evaluate the Pharmacokinetics and Bioequivalence of Sumatriptan Delivered Via the Intraject System Versus IMITREX STATdose at Three Injection Sites in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered by the
      Intraject system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, randomized, single-dose, open-label, partial-block, four-period, four-way
      crossover study in 54 healthy adult subjects to evaluate the pharmacokinetics and
      bioequivalence of sumatriptan delivered by the Intraject system compared to IMITREX STATdose
      at three injection sites (abdomen, thigh, and arm.)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve, maximal plasma concentration, time to maximal concentration, terminal elimination half-life, and apparent terminal elimination rate constant of sumatriptan will be determined at each of 3 sites</measure>
    <time_frame>one week</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sumatriptan (via Intraject System)</intervention_name>
    <description>0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Negative serum pregnancy test

          -  Female subjects of child-bearing potential must agree to use acceptable birth control
             3 weeks prior to and 2 weeks after study dosing.

          -  Body Mass Index (BMI) and sufficient subcutaneous thickness, in the opinion of the
             investigator, for an injection into the abdomen, arm and thigh

          -  Non-tobacco user

          -  Adequate venous access in the left or right arm to allow collection of a number of
             blood samples

          -  Fluent in the English language

          -  Provide written informed consent to participate in the study and be willing to comply
             with the study procedures

        Exclusion Criteria:

          -  History within the previous 2 years of drug or alcohol dependence

          -  Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal,
             hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder

          -  History of epilepsy or other neurologic disease

          -  History of coronary disease, peripheral vascular disease, cerebrovascular accident,
             transient ischemic attack, uncontrolled hypertension, or signs/symptoms of ischemic
             heart disease

          -  History of allergy, anaphylaxis, or hypersensitivity to sumatriptan or similar drugs
             including sulphonamides

          -  History of scleroderma or any skin condition that may adversely affect the injection
             or absorption of subcutaneously administered medications

          -  Tattoos or birthmarks in the lateral thigh, abdominal area or arm (deltoid) that are
             large enough to restrict injection site selection and/or evaluation

          -  Positive screening test for HIV antibodies, Hepatitis B surface antigen, or Hepatitis
             C antibody

          -  Positive results on illicit drug test at Screening or at Check-in

          -  Use of any prescription medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Chandler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance, Inc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>November 23, 2009</last_update_submitted>
  <last_update_submitted_qc>November 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stephen J. Farr, Ph.D/ President and COO</name_title>
    <organization>Zogenix, Inc</organization>
  </responsible_party>
  <keyword>sumatriptan</keyword>
  <keyword>Injections</keyword>
  <keyword>Subcutaneous</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

